KRON - Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement | Benzinga
SAN MATEO, Calif., and CAMBRIDGE, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to transforming the lives of those affected by cancer, today announced a streamlined leadership structure designed to focus on pipeline advancement and align with Kronos Bio's current operating needs. As part of this effort, Kronos Bio has eliminated three executive officer roles including the Chief Medical Officer, Chief Scientific Officer, and Chief Operating Officer and General Counsel. As a result, Jorge DiMartino, M.D., Ph.D., Christopher Dinsmore, Ph.D., and Barbara Kosacz, J.D., will be departing the Company. To ensure a smooth transition, they will remain with the Company through February 16, 2024. All three executives will remain strategic advisors to Kronos Bio.
"This new leadership structure is designed to streamline our operations and reflects our ongoing effort to advance our pipeline, optimize our resources, and efficiently deliver on our business objectives," said Norbert Bischofberger, Ph.D., President and Chief Executive Officer of Kronos Bio. "I would like to thank Jorge, Chris, and Barbara for their leadership and dedication, and I wish them well in their future endeavors. They each built and managed strong teams, laying the groundwork for this new structure and preparing our future leaders for success."
The Executive Leadership team, reporting to Dr. Bischofberger, now includes:
- Charles Lin, Ph.D., Senior Vice President, Research and Development
- Elizabeth Olek, DO, Senior Vice President, Clinical Development
- Rocio Martin Hoyos, Senior Vice President, Corporate Strategy and Portfolio Management
- Allison Frisbee, Senior Vice President, Corporate Operations and Legal
Each of these leaders brings robust and diverse experience with a focus in oncology. To learn more about the Kronos Bio leadership team, please visit: https://www.kronosbio.com/company/#leadership
"I am confident that Kronos Bio has the right leadership to progress the KB-0742 clinical program, advance KB-9558 through IND-enabling studies and beyond, and to continue to deliver on its collaborations," said Dr. DiMartino. "I'm honored to have ...